Figure 6.

Suppression of ataxin-7-92Q transgene expression in SCA7 mice after symptom onset does not prevent BG process loss. We immunostained cohorts of 43-week-old mice for GFAP, and noted that in comparison to tamoxifen-treated SCA7-negative mice (A), tamoxifen-treated SCA7 singly transgenic mice (B) have fewer, less organized and more stunted BG processes, and that this BG pathology is also apparent in both (C) tamoxifen-treated bigenic mice and (D) oil-treated bigenic mice. Scale bar, 25 µm. (E) Quantification of BG process numbers revealed that tamoxifen-treated bigenic mice display a significant loss of BG processes (P < 0.001, ANOVA with Bonferonni post-test), akin to tamoxifen-treated SCA7 singly transgenic mice or oil-treated bigenic mice. Error bars = SEM.